Recherche
-
A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica
(Annals of Clinical and Translational Neurology. vol. 8, n° 10, pp. 2025-2037, 2021-10)Article de revueLibre accès -
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
(Neurology. vol. 8, n° 4, 2021-04-26)Article de revueLibre accès -
Effect of cognitive rehabilitation on neuropsychological and semiecological testing and on daily cognitive functioning in multiple sclerosis: The REACTIV randomized controlled study
(2020-08-15)Document de travail - Pré-publicationLibre accès -
French validation of the Brief International Cognitive Assessment for Multiple Sclerosis
(Revue Neurologique. vol. 177, n° 1-2, pp. 73-79, 2021-01)Article de revue -
Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment
(Neurology(R) neuroimmunology & neuroinflammation. vol. 10, n° 6, 2023-09-22)Article de revueLibre accès -
Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype
(Brain Sciences. vol. 12, n° 2, pp. 183, 2022-01-29)Article de revueLibre accès -
Do isolated cognitive relapses exist? Commentary
(Multiple Sclerosis Journal. vol. 27, n° 10, pp. 1489-1490, 2021-09)Article de revueLibre accès -
Differential vulnerability of thalamic nuclei in multiple sclerosis
(Multiple Sclerosis Journal, 2022-08-12)Article de revueLibre accès -
Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal
(Neurotherapeutics. vol. 19, n° 2, pp. 476-490, 2022-03)Article de revueLibre accès -
Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.
(Neurology. vol. 100, n° 12, pp. e1296-e1308, 2023-03-21)Article de revueLibre accès